{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:45:50Z","timestamp":1792817150234,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-995882"],"award-info":[{"award-number":["R-995882"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2023\u20131055"],"award-info":[{"award-number":["FAI-2023\u20131055"]}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023670","name":"Nyckelfonden","doi-asserted-by":"publisher","award":["OLL-1000881"],"award-info":[{"award-number":["OLL-1000881"]}],"id":[{"id":"10.13039\/501100023670","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Professor Nanna Svartz Foundation","award":["2021\u201300436"],"award-info":[{"award-number":["2021\u201300436"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2024\u201343"],"award-info":[{"award-number":["2024\u201343"]}]},{"name":"Region Stockholm","award":["FoUI-1004114"],"award-info":[{"award-number":["FoUI-1004114"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-995557"],"award-info":[{"award-number":["R-995557"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2023\u20131006"],"award-info":[{"award-number":["FAI-2023\u20131006"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2024\u201349"],"award-info":[{"award-number":["2024\u201349"]}]},{"DOI":"10.13039\/501100009806","name":"Ulla and Gustaf af Uggla Foundation","doi-asserted-by":"publisher","award":["2023\u2013025029"],"award-info":[{"award-number":["2023\u2013025029"]}],"id":[{"id":"10.13039\/501100009806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Upon commencement of therapy for active disease, patients with systemic lupus erythematosus (SLE) show varying evolution regarding disease activity measures and patient-reported outcomes (PROs). Our objective was to identify disease evolution trajectories to gain a deeper understanding of SLE progression, ultimately improving future trial design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with \u22652 visits and available data on Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG), Physician Global Assessment (PGA), Functional Assessment of Chronic Illness Therapy\u2014Fatigue (FACIT-F), and glucocorticoid use were included in a post hoc analysis of four randomized controlled trials of belimumab (BLISS-52, BLISS-76, BLISS-SC, EMBRACE). Growth mixture modelling identified latent classes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 2868 patients analysed, baseline median disease duration was 4.5 (interquartile range: 1.5\u20139.7) years and mean (\u00b1standard deviation) Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) Damage Index (SDI) 0.7 (\u00b12.0), SLEDAI-2K 10.2 (\u00b13.6), BILAG 17.0 (\u00b17.8), PGA 1.5 (\u00b10.5), FACIT-F 30.6 (\u00b111.9) and prednisone dose 11.0 (\u00b18.9) mg\/day. In the initial model, glucocorticoid use and dose yielded high standard errors, indicating a weak link with the latent process. A refined model considered only clinical measures and FACIT-F, corrected for intervention and SDI; no other covariates improved the fit. Four classes best described disease evolution: highly active, responders; highly active, non-responders; moderately active, responders; moderately active, non-responders. Lupus Low Disease Activity State and Definitions of Remission in SLE remission attainment associated with latent classes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>By linking disease activity measures with PROs, we identified four distinct trajectories describing SLE evolution following the initiation of therapy. This classification could be valuable for personalizing treatment and guiding biological studies aimed at distinguishing patients with varying anticipated treatment responses, as no single clinical variable alone can predict disease progression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae575","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T14:48:49Z","timestamp":1729090129000},"page":"2697-2705","source":"Crossref","is-referenced-by-count":9,"title":["Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]},{"name":"Department of Rheumatology, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-9471","authenticated-orcid":false,"given":"Julius","family":"Lindblom","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4815-7477","authenticated-orcid":false,"given":"Alexander","family":"Tsoi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2652-7447","authenticated-orcid":false,"given":"Leonardo","family":"Palazzo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Blomkvist Sporre","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]},{"name":"Swedish Rheumatism Association , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9600-9995","authenticated-orcid":false,"given":"Yvonne","family":"Enman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]},{"name":"Swedish Rheumatism Association , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9894-6966","authenticated-orcid":false,"given":"Dionysis","family":"Nikolopoulos","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6529-6258","authenticated-orcid":false,"given":"Lorenzo","family":"Beretta","sequence":"additional","affiliation":[{"name":"Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico di Milano , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"2025050316123218200_keae575-B1","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025050316123218200_keae575-B2","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"2025050316123218200_keae575-B3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/03009742.2012.677857","article-title":"An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life","volume":"41","author":"Pettersson","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"2025050316123218200_keae575-B4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/art.23539","article-title":"Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease","volume":"59","author":"Campbell","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025050316123218200_keae575-B5","doi-asserted-by":"crossref","first-page":"651249","DOI":"10.3389\/fmed.2021.651249","article-title":"Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus","volume":"8","author":"Gomez","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025050316123218200_keae575-B6","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.3390\/jcm10163566","article-title":"Fatigue in systemic lupus erythematosus and rheumatoid arthritis: a comparison of mechanisms, measures and management","volume":"10","author":"Dey","year":"2021","journal-title":"J Clin Med"},{"key":"2025050316123218200_keae575-B7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0961203317722412","article-title":"Discordance of patient and physician health status concerns in systemic lupus erythematosus","volume":"27","author":"Golder","year":"2018","journal-title":"Lupus"},{"key":"2025050316123218200_keae575-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v078.i02","article-title":"Estimation of extended mixed models using latent classes and latent processes: the R package lcmm","volume":"78","author":"Proust-Lima","year":"2017","journal-title":"J Stat Softw"},{"key":"2025050316123218200_keae575-B9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10654-020-00615-6","article-title":"Identifying typical trajectories in longitudinal data: modelling strategies and interpretations","volume":"35","author":"Herle","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"2025050316123218200_keae575-B10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025050316123218200_keae575-B11","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025050316123218200_keae575-B12","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025050316123218200_keae575-B13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025050316123218200_keae575-B14","first-page":"8","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"2021","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025050316123218200_keae575-B15","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001202","article-title":"Impact of disease activity patterns on health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE)","volume":"11","author":"Elefante","year":"2024","journal-title":"Lupus Sci Med"},{"key":"2025050316123218200_keae575-B16","doi-asserted-by":"crossref","first-page":"1092325","DOI":"10.3389\/fmed.2022.1092325","article-title":"EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus","volume":"9","author":"Lindblom","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025050316123218200_keae575-B17","doi-asserted-by":"crossref","first-page":"152520","DOI":"10.1016\/j.semarthrit.2024.152520","article-title":"OMERACT systemic lupus erythematosus domain survey","volume":"68","author":"Nielsen","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316123218200_keae575-B18","doi-asserted-by":"crossref","first-page":"152380","DOI":"10.1016\/j.semarthrit.2024.152380","article-title":"OMERACT 2023 systemic lupus erythematosus special interest group: winnowing and binning preliminary candidate domains for the core outcome set","volume":"65","author":"Nielsen","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316123218200_keae575-B19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2025050316123218200_keae575-B20","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025050316123218200_keae575-B21","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025050316123218200_keae575-B22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of Black African Ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025050316123218200_keae575-B23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"2025050316123218200_keae575-B24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncr.10245","article-title":"Fatigue in cancer patients compared with fatigue in the general United States population","volume":"94","author":"Cella","year":"2002","journal-title":"Cancer"},{"key":"2025050316123218200_keae575-B25","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","article-title":"General population norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue scale","volume":"21","author":"Montan","year":"2018","journal-title":"Value Health"},{"key":"2025050316123218200_keae575-B26","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"2025050316123218200_keae575-B27","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q J Med"},{"key":"2025050316123218200_keae575-B28","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025050316123218200_keae575-B29","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/rheumatology\/keq026","article-title":"Numerical scoring for the BILAG-2004 index","volume":"49","author":"Yee","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316123218200_keae575-B30","doi-asserted-by":"crossref","first-page":"2050312116671725","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: scoping review","volume":"4","author":"Lins","year":"2016","journal-title":"SAGE Open Med"},{"key":"2025050316123218200_keae575-B31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"2025050316123218200_keae575-B32","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1002\/art.20628","article-title":"The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity","volume":"50","author":"American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2025050316123218200_keae575-B33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3899\/jrheum.100799","article-title":"Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial","volume":"38","author":"Lai","year":"2011","journal-title":"J Rheumatol"},{"key":"2025050316123218200_keae575-B34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/03009742.2014.988173","article-title":"Determination of the minimal clinically important difference for seven measures of fatigue in Swedish patients with systemic lupus erythematosus","volume":"44","author":"Pettersson","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2025050316123218200_keae575-B35","doi-asserted-by":"crossref","first-page":"e020683","DOI":"10.1136\/bmjopen-2017-020683","article-title":"Framework to construct and interpret latent class trajectory modelling","volume":"8","author":"Lennon","year":"2018","journal-title":"BMJ Open"},{"key":"2025050316123218200_keae575-B36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2025050316123218200_keae575-B37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1214\/aos\/1176344136","article-title":"Estimating the dimension of a model","volume":"6","author":"Schwarz","year":"1978","journal-title":"Ann Stat"},{"key":"2025050316123218200_keae575-B38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13075-021-02584-x","article-title":"Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models","volume":"23","author":"Reynolds","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025050316123218200_keae575-B39","doi-asserted-by":"crossref","first-page":"1074044","DOI":"10.3389\/fimmu.2022.1074044","article-title":"Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: a real-life, multicentre observational study","volume":"13","author":"Nikoloudaki","year":"2022","journal-title":"Front Immunol"},{"key":"2025050316123218200_keae575-B40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/acr2.11417","article-title":"Anxiety symptoms among patients with systemic lupus erythematosus persist over time and are independent of SLE disease activity","volume":"4","author":"Lew","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2025050316123218200_keae575-B41","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00296-024-05546-z","article-title":"Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional study","volume":"44","author":"Gomez","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025050316123218200_keae575-B42","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/0961203320983892","article-title":"Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years","volume":"30","author":"Moazzami","year":"2021","journal-title":"Lupus"},{"key":"2025050316123218200_keae575-B43","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/jcm11020340","article-title":"Patient-reported outcomes in systemic lupus erythematosus. can lupus patients take the driver's seat in their disease monitoring?","volume":"11","author":"Parodis","year":"2022","journal-title":"J Clin Med"},{"key":"2025050316123218200_keae575-B44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41584-023-00993-7","article-title":"Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce","volume":"19","author":"Connelly","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025050316123218200_keae575-B45","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.42920","article-title":"Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: a systematic review and meta-analysis of the control arms of randomized controlled trials","volume":"76","author":"Figueroa-Parra","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025050316123218200_keae575-B46","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.3390\/jcm9092709","article-title":"Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues","volume":"9","author":"Porta","year":"2020","journal-title":"J Clin Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae575\/60254442\/keae575.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2697\/60254442\/keae575.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2697\/60254442\/keae575.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:12:50Z","timestamp":1746303170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2697\/7824072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,16]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae575","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,10,16]]}}}